Wed, Nov 26, 2014, 3:53 PM EST - U.S. Markets close in 7 mins.


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • mynameissteve258 mynameissteve258 Aug 22, 2013 1:02 PM Flag

    Goldman maintains Sell rating on Incyte after Jakafi results LINK

    Seeking Alpha Market Currents
    Goldman maintains Sell rating on Incyte after Jakafi results

    "The Street is assigning value to Jakafi in other solid cancers (e.g., lung cancer), which we believe is premature given lack of data and limited visibility on subgroup criteria," Goldman's Navdeep Singh says, regarding the huge run up in shares of Incyte (INCY -4.5%) following the release of data from a Phase 2 pancreatic cancer study.
    Goldman maintains its Sell rating on the shares.
    Price target is $26, some 28% lower than Wednesday's close.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
74.71+1.57(+2.15%)3:52 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.